Free Trial

Mackie's Rating of Khiron Life Sciences on 11/30/2022

On November 30, 2022, Mackie updated its outlook on Khiron Life Sciences (OTCMKTS:KHRNF) with the action "Downgrade", setting a "Hold" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Mackie

DateCompanyAction
3/11/2025
Knight Therapeutics Inc. stock logo
KHTRF
Knight Therapeutics
Upgrade
10/10/2023
Canacol Energy Ltd stock logo
CNNEF
Canacol Energy
Downgrade
3/29/2022
Logiq, Inc. stock logo
LGIQ
Logiq
Initiated Coverage
10/16/2020
Theratechnologies Inc. stock logo
THTX
Theratechnologies
Reiterated Rating
More Ratings From Mackie